Efficacia della Rufinamide nelle encefalopatie epilettiche secondarie a malformazioni cerebrali complesse

Translated title of the contribution: Efficacy of Rufinamide in epileptic encephalopathies secondary to complex brain malformations

F. Madeddu, R. Moavero, D. Battaglia, S. Matricardi, G. Coppola, M. Balestri, A. Capuano, P. Curatolo, A. Verrotti, F. Vigevano, D. Pruna, R. Cusmai

Research output: Contribution to journalArticlepeer-review

Abstract

Aim of this study was the evaluation of efficacy and tolerability of an add-on rufinamide (RFN) trial in 33 patients with epileptic encephalopathies secondary to complex brain malformations. Patients have been considered responders if seizure reduction was greater than 50%. 19/33 patients (57.6%) are responders: in particular in 9 patients seizure's reduction was greater than 50% and in 10 was greater than 75%. The mean follow-up was 15.1 months (8-36 months). All non-responder patients (42.4%) discontinued rufinamide. 21,2% of subjects presented mild and transient side effects. In one case (3,1%) RFN was discontinued because of persisting anorexia. In a another case RFN was discontinued for an increase of seizures. Our results suggest that rufinamide can be considered as a valuable adjunctive therapeutic option in epileptic encephalopathies secondary to complex brain malformations).

Translated title of the contributionEfficacy of Rufinamide in epileptic encephalopathies secondary to complex brain malformations
Original languageItalian
Pages (from-to)278-280
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number145
Publication statusPublished - Apr 2013

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Efficacy of Rufinamide in epileptic encephalopathies secondary to complex brain malformations'. Together they form a unique fingerprint.

Cite this